Clinical trial NCT02086591 (phase 2, status: terminated)
Conditions: adult diffuse large b-cell lymphoma, mantle cell lymphoma recurrent, lymphoma, follicular, marginal zone b-cell lymphoma, malignant lymphoma - lymphoplasmacytic, waldenstrom macroglobulinemia, small lymphocytic lymphoma, chronic lymphocytic leukemia (cll), t-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C88.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, A87.2, K52.832, D72.111, C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: doxycycline
SMILES: [H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed aggressive or indolent NHL following any prior treatment of the following
             etiologies:

               -  Diffuse large B cell lymphoma (DLBCL)

               -  Mantle cell lymphoma (MCL)

               -  Follicular lymphoma (FL)

               -  Marginal zone lymphoma (MZL)

               -  Lymphoplasmacytic lymphoma (LPL)

               -  Waldenstrom's macroglobulinemia (WM)

               -  Small lymphocytic lymphoma (SLL)

               -  Chronic lymphocytic leukemia (CLL)

               -  T cell lymphoma (TCL)

          -  Ages ≥ 18

          -  Karnofsky Performance Status (KPS) ≥ 60% or Eastern Cooperative Oncology Group
             Performance Status (ECOG PS) ≤2

          -  Life expectancy of at least 3 months

          -  Measurable disease in at least one target lesion, assessable by radiographic
             examination with Fludeoxyglucose-Positron Emission Tomography (FDG-PET) or computed
             tomography (CT), bone marrow evaluation showing involvement, or peripheral blood
             showing involvement of lymphoma

          -  Adequate organ function:

               -  Absolute neutrophil count (ANC) > 500 cells/mL and platelet count > 50,000
                  cells/mL unless felt to be secondary to lymphoma at which any count is
                  permissible.

               -  Adequate renal function as determined by Creatinine (Cr) < 1.5x upper limit of
                  normal (ULN) or estimated creatinine clearance of ≥ 60mL/min

               -  Adequate hepatic function as determined by total bilirubin < 1.5x upper limit of
                  normal (ULN) (unless known Gilbert syndrome), alanine aminotransferase (ALT)and
                  aspartate aminotransferase (AST) < 2.5x upper limit of normal (ULN)

        Exclusion Criteria:

          -  Known sensitivity or allergy to tetracyclines

          -  Lack of measurable disease by computed tomography (CT) or Fludeoxyglucose-Positron
             Emission Tomography (FDG-PET)

          -  Karnofsky Performance Status (KPS) <60% or Eastern Cooperative Oncology Group
             Performance Status (ECOG PS) >2

          -  Curative treatment is indicated or possible

          -  Inadequate organ function as measured by not fulfilling above criteria

          -  Pregnancy, positive serum human chorionic gonadotropin (hCG) within 28 days of
             enrollment, or breast-feeding.